Key contacts

Will Corkill

Will Corkill
Director

Simon Wilson

Simon Wilson
Director

Regional office - Australia
Level 25
Aurora Place
88 Phillip Street
Sydney
NSW 2000
Australia
Tel: +61 (0)2 9258 1161

Regional office - New Zealand
Level 15
171 Featherston Street
Wellington 6011
New Zealand
Tel: +64 (0)4 8948555

swilson@edisongroup.com
wcorkill@edisongroup.com

listed companies

Range Resources Nkwe Platinum
MEC Resources Coal of Africa
Syndicated Metals Gold One
Bionomics Allied Gold Mining
Phylogica ADX Energy
Alkane Resources Bellzone Mining
Sumatra Copper & Gold Continental Coal
Gunson Resources RedFlow
Lochard Energy Circadian Technologies
Universal Coal Biotron
See more

Companies with HQs in asia-pacific

Seeing Machines Forterra Trust
Greka Drilling Bezant Resources
Green Dragon Gas Baobab Resources
Endace Wynnstay Group
PXP Vietnam Fund Chatham Rock Phosphate
Tenon MMG
SeaDragon Contact Energy
Cue Energy New Zealand Oil & Gas
Rubicon Sky Network Television
Pura Vida Energy Sealegs Corporation
See more

Latest research

Alkane Resources

Ahead of target and reconfiguring the TGO

Update | Mining | 15/10/2014

The TGO continues to outperform, with gold production ahead of our Q115 estimate and at low quartile total cash operating costs of A$867/oz. Continued positive mine-to-mill reconciliations have now resulted in Alkane reviewing its resource base and mine planning with a view to optimising the TGO’s future production profile. This could bring forward underground production and combine the planned Caloma and Caloma Two open pits.

Prima BioMed

Daily comment

Institutional Comment | Pharmaceutical & Healthcare | 10/10/2014

Prima BioMed is an ASX-listed biotechnology company focused on immunotherapy. Its lead product candidate, CVac, is a novel autologous dendritic cell immunotherapy in development for ovarian cancer patients in second remission and pancreatic cancer patients.

Prima BioMed

From product to pipeline

Update | Pharmaceutical & Healthcare | 09/10/2014

Prima BioMed is in the process of completing a transformational acquisition, moving it from being a one-product company to one with a promising pipeline of immunotherapy assets. It is purchasing the private French company, Immutep, for a total consideration of up to c US$28m to obtain a pipeline of two clinical assets (one partnered with GSK) and a preclinical development programme. Linked to the acquisition, Prima BioMed has arranged a financing facility with Bergen of up to US$37.4m.

99 Wuxian

High-growth m-commerce play needs funding

QuickView | Consumer Support Services | 07/10/2014

99 Wuxian was profitable in its first year and continues to grow rapidly. Substantial potential remains. However, it lacks the funding to attack that potential and has launched a strategic review of its listing and capital structure to address how best to fund growth. In the short term, negotiations over the pricing of any fund-raising are likely to set the base for valuation.

GNI Group Ltd

Poised for the next phase

QuickView | Pharmaceutical & Healthcare | 07/10/2014

GNI is close to advancing its lead product Etuary (pirfenidone) into pivotal clinical studies in radiation pneumonitis, diabetic nephropathy and other fibrotic diseases. Etuary is commercialised in China for idiopathic pulmonary fibrosis (IPF). The company has global patents for Etuary, and for F351, its improved chemical entity, which is due to move into Phase II for liver fibrosis and potentially chronic kidney disease (CKD), both of which are prevalent in global populations. As GNI moves further…

About

Edison‘s Sydney and Wellington offices opened in 2011 to provide research services to companies listed on Asia-Pacific stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of research and unrivalled distribution of our reports on a global and unrestricted basis.

Sector Commentary

See more reports See more reports See more reports

Sector Reports

See more sector reports See more sector reports